Addex

Allosteric modulators for human health

  • About us
    • Addex Corporate Presentation
    • Overview
    • Our people
      • Executive Officers
      • Non-Executive Directors
      • Scientific Advisory Board
    • Contact
    • Privacy Policy
    • Careers
  • Pipeline
    • Clinical and Pre-Clinical Pipeline
    • Research And Development
  • Technology platform
    • Allosteric modulation
    • Our capabilities
      • Screening Assays
      • Chemistry
    • Publications
  • Partners & collaboration
  • Investors
    • Addex Corporate Presentation
    • Stock Data
    • Press releases
    • Ad hoc announcements (Art. 53 L.R)
    • Events
    • Financial Reports
    • Analyst Reports
    • General Meetings
    • SEC / SIX Filings
    • Guide to US ADSS for Six Shareholders
    • Register for email news
    • Corporate Governance
    • Contact
  • Media
    • Press releases
    • Contact
about us

about us

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

Pipeline

Clinical and Pre-Clinical Pipeline

 

 

 

Research And Development

   

 

Publications
  • GABAB PAM for cough
  • M4 PAM for schizophrenia & other psychosis
  • ADX71149 for epilepsy
  • GABAB PAM for substance use disorder
  • Dipraglurant for post-stroke sensorimotor recovery
  • mGlu7 NAM for stress related disorders including PTSD
  • mGlu2 NAM for mild neurocognitive disorders
Placeholder image

Technology platform

Allosteric Modulation

Read more
Placeholder image

Partners & Collaborations

Industry

Read more

Latest news Latest news icon

  • 12.15
    2009

    Development of ADX10059 Ended for Long-term Use

  • 12.14
    2009

    Addex Ends Migraine Prevention Study

  • 12.02
    2009

    Addex Extends Parkinson’s Disease Collaboration with Merck & Co., Inc.

  • 11.24
    2009

    Addex ADX48621 Positive Primate Parkinson’s Data

  • 11.16
    2009

    Addex ADX10059 Monotherapy is Effective on GERD Symptoms in Phase IIb Clinical Trial

  • 11.03
    2009

    Addex Presents ADX10059 PD-LID Data at GPCR Drug Discovery Conference

  • 09.28
    2009

    Addex completes enrollment of first mid-stage clinical GERD trial

  • 09.17
    2009

    Laurent Massuyeau, Head of Business Development, Resigns

  • 09.14
    2009

    Addex’ ADX10059 has potential for Parkinson’s disease levodopa induced dyskinesia (PD-LID)

  • 07.28
    2009

    Addex Pharmaceuticals Reports First Half 2009 Financial Results

    Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • Next

Contact us

If you have any questions please let me know
  • Contact form
2026 © Addex therapeutics